Business Context and Reporting Period
Company: PerkinElmer, Inc. (Note: Metadata lists "REVVITY, INC." but the filing text identifies the registrant as PerkinElmer, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: November 29, 2002
Reporting Period: Fiscal years ended December 30, 2001, and December 31, 2000.
This filing serves to submit audited consolidated financial statements and a press release announcing a planned private placement of senior subordinated notes. The financial statements reflect a reclassification of the Fluid Sciences business unit as a continuing operation (previously planned for sale) and the Telecommunications Component and Entertainment Lighting businesses as discontinued operations.
Key Financial Metrics
| Metric | Fiscal 2001 | Fiscal 2000 |
|---|---|---|
| Total Sales | $1,525.3 million | $1,538.0 million |
| Operating Income | $129.7 million | $179.9 million |
| Net Income | $34.5 million | $90.5 million |
| Adjusted Net Income (Non-GAAP) | $152.3 million | $126.8 million |
| Adjusted EBITDA (Non-GAAP) | $291.2 million | $255.0 million |
| Operating Cash Flow | $145.3 million | $156.9 million |
| Total Assets | $2,969.9 million | $2,260.8 million |
| Total Debt (Short + Long Term) | $724.1 million | $768.7 million |
| Cash and Equivalents | $138.3 million | $125.6 million |
Material Changes vs. Prior Period
- Revenue: Total sales decreased slightly by 1% ($12.6 million) to $1,525.3 million. Organic sales were flat, with growth in Life Sciences offset by declines in Optoelectronics and Fluid Sciences.
- Profitability: GAAP Net Income dropped significantly to $34.5 million from $90.5 million, primarily due to a $69.0 million charge for in-process research and development (IPR&D) related to the Packard BioScience acquisition and a $117.8 million goodwill impairment charge recorded as an accounting change in Q1 2002 (impacting the 2002 outlook).
- Adjusted Performance: On an adjusted basis (excluding nonrecurring items and amortization), Net Income increased 20% to $152.3 million, and Adjusted EBITDA rose 14% to $291.2 million.
- Segment Performance:
- Life Sciences: Sales surged 56% to $346.1 million due to the Packard BioScience and NEN Life Sciences acquisitions.
- Optoelectronics: Sales fell 15% to $380.2 million due to weakness in photography and semiconductor markets.
- Fluid Sciences: Sales declined 8% to $230.6 million.
- Acquisitions & Divestitures: Completed the acquisition of Packard BioScience ($733 million) in late 2001. Sold the Security and Detection Systems business in June 2002 for approximately $100 million.
Guidance, Outlook, and Risks
- Restructuring & Cost Savings: Management combined Life Sciences and Analytical Instruments into a single business unit. They target annualized cost savings of $30.0 million to $45.0 million, with $12.0 million to $25.0 million expected in 2003. Full benefits are not expected until 2004.
- Market Conditions: Operating results in 2002 were adversely affected by downturns in pharmaceutical, biomedical, semiconductor, and aerospace markets. Management expects these trends to continue into 2003.
- Liquidity & Debt: The company plans a private placement of senior subordinated notes. Significant debt maturities include zero coupon convertible debentures (put option in August 2003) and $115 million in notes due in 2005. Credit facilities were amended in September 2002, reducing capacity and increasing interest spreads.
- Contingencies:
- Environmental: Accrued $12.1 million for environmental remediation; potential for additional liability exists but is not estimable.
- Legal: Named as a defendant in a class-action lawsuit regarding misleading statements; loss amount cannot be estimated.
Investor Verification Checklist
- Debt Refinancing: Verify the status of the planned private placement of senior subordinated notes and the ability to refinance the $403.8 million zero coupon convertible debentures due in August 2003.
- Goodwill Impairment: Confirm the impact of the $117.8 million goodwill impairment charge on future earnings and the valuation of the Optoelectronics lighting reporting unit.
- Cost Savings Realization: Monitor the actual realization of the targeted $30M-$45M annualized cost savings from the Life Sciences/Analytical Instruments integration.
- Market Exposure: Assess the continued impact of the semiconductor and aerospace downturns on the Fluid Sciences and Optoelectronics segments.
- Legal & Environmental: Track developments in the class-action lawsuit and environmental remediation costs to ensure they do not exceed current accruals.